论文部分内容阅读
目的探讨美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的临床疗效。方法将82例溃疡性结肠炎患者随机分为治疗组和对照组,治疗组42例,对照组40例。治疗组给予美沙拉嗪,对照组给予柳氮磺胺吡啶,治疗疗程均为6个月。比较两组的疗效和不良反应发生情况。结果对照组临床总有效率67.5%,治疗组总有效率为83.3%,两组比较差异显著(P<0.05)。腹泻、腹痛、黏液血便,治疗组的总有效率分别为85.4%、86.8%和91.7%,对照组分别为78.9%、75.7%、73.5%。与对照组相比,治疗组腹泻、腹痛、黏液血便等疗效改善情况明显较好(P<0.05);与对照组相比,治疗组不良反应发生率明显较低(P<0.05)。结论美沙拉嗪治疗溃疡性结肠炎疗效确切,不良反应发生率低,值得临床推广。
Objective To investigate the clinical efficacy of mesalazine and sulfasalazine in the treatment of ulcerative colitis. Methods 82 patients with ulcerative colitis were randomly divided into treatment group and control group, 42 cases in the treatment group and 40 cases in the control group. The treatment group was given Mesalazine, the control group was given sulfasalazine, the treatment course was 6 months. The curative effect and adverse reaction of the two groups were compared. Results The total effective rate in the control group was 67.5%, and the total effective rate in the treatment group was 83.3%. There was significant difference between the two groups (P <0.05). Diarrhea, abdominal pain, bloody mucus, the total effective rate of the treatment group were 85.4%, 86.8% and 91.7%, respectively, the control group were 78.9%, 75.7%, 73.5%. Compared with the control group, the curative effect of diarrhea, abdominal pain and bloody mucus in the treatment group was significantly better (P <0.05). Compared with the control group, the incidence of adverse reactions in the treatment group was significantly lower (P <0.05). Conclusion Mesalazine is effective in treating ulcerative colitis with low incidence of adverse reactions and is worthy of clinical promotion.